A Systematic Review and Meta-Analysis of Combined Cognitive and Physical Interventions on Cognition Function in Frail Older Adults.

J Am Med Dir AssocJul 21, 2026 (epub)
Clinical ResearchGeriatrics

Zhong Li, Rixin Qin, Jiaxin Lv et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of combined cognitive and physical interventions on cognitive function, frailty, gait speed, and depression in frail older adults. Eleven randomized controlled trials with 989 participants were analyzed, revealing significant improvements in global cognitive function (SMD, 1.05; P < .001), frailty (SMD, -1.03; P < .001), and gait speed (SMD, 1.12; P = .0008), while depressive symptoms showed no significant change.

Key findings

  • Combined interventions significantly improved global cognitive function (SMD, 1.05; P < .001).
  • There was a significant reduction in frailty levels (SMD, -1.03; P < .001).
  • Gait speed improved significantly (SMD, 1.12; P = .0008).
  • No significant improvement in depressive symptoms (SMD, -0.36; P = .53).

Why it matters

The findings suggest that integrated physical and cognitive interventions can enhance cognitive function and reduce frailty in older adults, which is crucial for maintaining independence and quality of life in this population.

Source

PubMed · PMID 42480329

Published in J Am Med Dir Assoc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.